Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) EBIT (2016 - 2025)

Integra Lifesciences Holdings' EBIT history spans 17 years, with the latest figure at $23.0 million for Q4 2025.

  • For Q4 2025, EBIT fell 35.33% year-over-year to $23.0 million; the TTM value through Dec 2025 reached -$493.4 million, down 1836.55%, while the annual FY2025 figure was -$493.4 million, 1836.55% down from the prior year.
  • EBIT for Q4 2025 was $23.0 million at Integra Lifesciences Holdings, up from $11.8 million in the prior quarter.
  • Across five years, EBIT topped out at $67.8 million in Q4 2022 and bottomed at -$512.7 million in Q2 2025.
  • The 5-year median for EBIT is $33.2 million (2021), against an average of $4.1 million.
  • The largest annual shift saw EBIT skyrocketed 268.28% in 2021 before it crashed 16825.52% in 2025.
  • A 5-year view of EBIT shows it stood at $58.2 million in 2021, then grew by 16.52% to $67.8 million in 2022, then tumbled by 46.86% to $36.0 million in 2023, then fell by 1.17% to $35.6 million in 2024, then tumbled by 35.33% to $23.0 million in 2025.
  • Per Business Quant, the three most recent readings for IART's EBIT are $23.0 million (Q4 2025), $11.8 million (Q3 2025), and -$512.7 million (Q2 2025).